

Date	Room	Time	Topic	Lecturer/Expert	Affiliation (1)
<b>Day 1: MON 13th June, 2016</b>	ARM 108	9-10:15 am	Introduction to the Course	Jagesh Shah, PhD	HMS/BWH/HST
		10:30-12 pm	Unmet Medical Needs	Mark Fishman, MD	Novartis
		1-3 pm	Statins and cholesterol-reducing drugs	Paul Ridker, MD	BWH
				David Cohen, MD, PhD	BWH
		3-5 pm	Unmet Medical Needs Exercise	Donna Polk, MD, MPH	BWH
Catherine Dubreuil, PhD	HMS				
<b>Day 2: TUE 14th June, 2016</b>	ARM 108	9-10 am	Patient Visit - Polycystic Kidney Disease (PKD)	Mike and Samantha Fratus	
				Julie Jonassen, PhD	UMASS Med
				Theodore Steinman, MD	BIDMC/BWH
		10:15 am-12 pm	PKD case panel	Julie Jonassen, PhD	UMASS Med
				Jagesh Shah, PhD	HMS/BWH/HST
				Theodore Steinman, MD	BIDMC/BWH
		1-2 pm	Introduction to Gleevec case	Oxana Beskrovnaya, PhD	Genzyme
				Megan Mittelstadt, PhD	HMS
		2-4 pm	How do research discoveries get turned into therapies?	Jeff Karp, PhD	BWH
				Lauren Foster, DSc	MIT Tech. Licensing Office
Geoffery von Maltzahn, PhD	Flagship VentureLabs				
<b>Day 3: WED 15th June, 2016</b>	ARM 108	9-10 am	Drug Screening and Structure-based drug design	Sara Buhrlage, PhD	DFCI
		10:10-11:30 am	Drug Pharmacology	Tim Mitchison, PhD	HMS
		11:30-12:30 pm	Pre-clinical animal toxicity	Tim McLachlan, PhD	Novartis
		1-4 pm	Break --- work on their Gleevec Case		
<b>Day 4: THU 16th June, 2016</b>	ARM 108	9-10:45 am	Models of disease	Larry Benowitz, PhD	BCH
				Wolfram Goessling, MD, PhD	BWH
				Sanyal Subhabrata, PhD	Biogen IDEC
				Kevin Croce MD, PhD	BWH
		11 am-12:15 pm	Break --- work on their Gleevec Case		
		1-3 pm	When drugs stop working - Drug Resistance	Alyssa Letourneau, MD, MPH	MGH
				Don Coen, PhD	HMS
Dan Kuritzkes, MD	BWH				
3:15-5 pm	Moving into humans: Clinical trial design	Anna Farago, MD, PhD	MGH		
<b>Day 5: FRI 17th June, 2016</b>	ARM 108	9-10:30 am	Phase I: Testing Drug Toxicity in Healthy Humans	Mark Goldberg, MD	BWH
		10:30-12 pm	Phase II: Surrogate endpoints in a tuberculosis drug	Jennifer Wheler, MD	Novartis
		1-2 pm	Phase III: HIV vaccines and cohort selection	Eric Rubin, MD, PhD	HSPH/HMS
		2-5 pm	Gleevec case presentations	Filippos Porichis, PhD	The Ragon Institute
				Megan Mittelstadt, PhD	HMS
Andrew Wylie, PhD	Novartis				
Daniel DeAngelo, MD, PhD	DFCI				

Date	Room	Time	Topic	Lecturer/Expert	Affiliation (1)
Day 6: MON 20th June, 2016	TMEC L-008	9-9:30 am	Looking back and forward	Jagesh Shah, PhD	HMS/BWH/HST
		9:30-11:30 am	Patient advocacy driving science and approval	Ed Harlow, PhD	HMS/NCI
				Jeffrey Kauffman	Adenoid Cystic Carcinoma Research
		11:30-12 pm	Introduction to Alzheimer's case	Catherine Dubreuil, PhD	HMS
		1-2:30 pm	TBD	Noubar Afeyan, PhD	Flagship Ventures
		2:30-3:30 pm	AD Case work		
		3:30-5 pm	Adaptive Licensing in Precision Medicine	Mark Trusheim, PhD	MIT
Day 7: TUE 21th June, 2016	TMEC L-008	9-10:15 am	Phase IV: Pharmacovigilance	Krista Huybrechts, PhD	BWH
		10:30 am-12:30 pm	Vioxx Case	Aaron Kesselheim, MD, JD, MPH	BWH
				Krista Huybrechts, PhD	BWH
		1:30-4:00 pm	Challenges in medical device development	Fred Schoen, MD, PhD	BWH/HMS/HST
4-5 pm	Human Genetics and the Discovery of New Medicines	David Altshuler, MD, PhD	Vertex Pharmaceuticals		
Day 8: WED 22nd June, 2016	Modell 100A	9-10:30 am	Biomarkers	Vishal Vaidya, PhD	BWH
		10:45 am-12 pm	Pharmacogenomics	Peter Shaw, PhD	Merck
		1-3 pm	HIV Biomarkers and companion diagnostics	Boris Juelg, MD, PhD	MGH/The Ragon Institute
		3-4:30 pm	Imaging as a biomarker/diagnostic	John Chen, MD, PhD	MGH
Day 9: THU 23rd June, 2016	TMEC L-007	9am-12:30 pm	Alzheimer's Disease case presentation and wrap up	<b>TBD</b>	<b>TBD</b>
				Catherine Dubreuil, PhD	HMS
				Dominic Walsh, PhD	BWH
1:30-2:45 pm	Paper-based point of care diagnostics	Shekar Shetty, PhD	Diagnostics for All		
3-4:30 pm	Checkpoint Inhibition in the Treatment of Cancer	Edward Garmey, MD	Alacrita Consulting, LLC		
Day 10: FRI 24th June, 2016	TMEC L-007	9-10:15 am	Why Highly Effective Drugs Are Not Enough: An Affordable Solution to Eliminating HCV	Ann Kwong, PhD	TREK Therapeutics, PBC
		10:30 am-12 pm	HIV and Cryptococcal Meningitis: Implementing a low cost point of care assay for early detection and prevention	Tariro Makadzange, MD, PhD	Ragon Institute/MGH
		1-2:30 pm	How to get insurance companies to pay for your drugs: Formulating a strategy	David Balekdjian	Bruckner Group
		2:30-4 pm	Bioengineering of circulating tumor cell microchip: from concept-to-clinical trials	Mehmet Toner, PhD	HMS/MGH/HST

(1) HMS - Harvard Medical School, BWH - Brigham and Women's Hospital, MGH - Massachusetts General Hospital, DFCI, Dana Farber Cancer Institute, BCH - Boston Children's Hospital, BIDMC - Beth Israel Deaconess Medical Center MIT - Massachusetts Institute of Technology, HST - Harvard/MIT Division of Health Sciences and Technology HSPH - Harvard School of Public Health